SELLAS Life Sciences (SLS) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $9.98, -11.99% vs the prior close of $11.34.
- Volume 15.77M shares, 2.5x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SLS slides 12.0% to $9.98, a 3-month low on 2.5x normal volume. Closed at $9.98, -11.99% vs the prior close of $11.34. Day range $9.75–$11.24, opened at $11.17.
SLS daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — SLS slides 12.0% to $9.98, a 3-month low on 2.5x normal volume
- Closed at $9.98, -11.99% vs the prior close of $11.34. Day range $9.75–$11.24, opened at $11.17.
- Volume was 15.77M shares, 2.5x its 50-day average of 6.29M — unusually heavy trading.
- Price is -19.6% vs its 50-day average ($12.42) and +21.4% vs its 200-day average ($8.22).
- 52-week range $1.39–$15.88; today's close sits at 59% of that range, 37.2% below the 52-week high.
- That makes 3 straight losses.
Oct 15, 2026 — SLS slides 4.5% to $11.34
- Closed at $11.34, -4.55% vs the prior close of $11.88. Day range $11.15–$11.92, opened at $11.50.
- Volume was 4.65M shares, 0.7x its 50-day average of 6.31M.
- Price is -9.0% vs its 50-day average ($12.46) and +38.5% vs its 200-day average ($8.19).
- 52-week range $1.39–$15.88; today's close sits at 69% of that range, 28.6% below the 52-week high.
Oct 14, 2026 — SLS slides 4.3% to $11.88
- Closed at $11.88, -4.27% vs the prior close of $12.41. Day range $11.71–$12.44, opened at $12.21.
- Volume was 4.74M shares, 0.8x its 50-day average of 6.32M.
- Price is -4.7% vs its 50-day average ($12.47) and +45.8% vs its 200-day average ($8.15).
- 52-week range $1.39–$15.88; today's close sits at 72% of that range, 25.2% below the 52-week high.
Oct 13, 2026 — SLS jumps 4.0% to $12.41, a 1-month high, 3 up days in a row
- Closed at $12.41, +4.02% vs the prior close of $11.93. Day range $11.69–$12.70, opened at $11.74.
- Volume was 6.40M shares, 1.0x its 50-day average of 6.33M.
- Price is -0.4% vs its 50-day average ($12.46) and +53.2% vs its 200-day average ($8.10).
- 52-week range $1.39–$15.88; today's close sits at 76% of that range, 21.9% below the 52-week high.
- That makes 3 straight gains.
Oct 12, 2026 — SLS rises 2.4% to $11.93
- Closed at $11.93, +2.40% vs the prior close of $11.65. Day range $11.48–$12.14, opened at $11.58.
- Volume was 4.03M shares, 0.6x its 50-day average of 6.35M.
- Price is -4.1% vs its 50-day average ($12.44) and +48.1% vs its 200-day average ($8.05).
- 52-week range $1.39–$15.88; today's close sits at 73% of that range, 24.9% below the 52-week high.
Oct 9, 2026 — SLS jumps 3.5% to $11.65
- Closed at $11.65, +3.46% vs the prior close of $11.26. Day range $11.26–$11.81, opened at $11.38.
- Volume was 4.18M shares, 0.7x its 50-day average of 6.35M.
- Price is -6.1% vs its 50-day average ($12.40) and +45.5% vs its 200-day average ($8.01).
- 52-week range $1.39–$15.88; today's close sits at 71% of that range, 26.6% below the 52-week high.
Oct 8, 2026 — SLS dips 0.4% to $11.26, a 1-month low, 4 down days in a row
- Closed at $11.26, -0.44% vs the prior close of $11.31. Day range $10.71–$11.34, opened at $11.17.
- Volume was 4.21M shares, 0.7x its 50-day average of 6.38M.
- Price is -9.0% vs its 50-day average ($12.37) and +41.4% vs its 200-day average ($7.96).
- 52-week range $1.39–$15.88; today's close sits at 68% of that range, 29.1% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 — SLS ends flat (-0.3%) to $11.31, 3 down days in a row
- Closed at $11.31, -0.26% vs the prior close of $11.34. Day range $11.15–$11.54, opened at $11.28.
- Volume was 3.13M shares, 0.5x its 50-day average of 6.52M — lighter than usual.
- Price is -8.4% vs its 50-day average ($12.35) and +42.8% vs its 200-day average ($7.92).
- 52-week range $1.39–$15.88; today's close sits at 68% of that range, 28.8% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — SLS dips 2.5% to $11.34
- Closed at $11.34, -2.49% vs the prior close of $11.63. Day range $11.11–$11.67, opened at $11.63.
- Volume was 3.98M shares, 0.6x its 50-day average of 6.62M.
- Price is -8.0% vs its 50-day average ($12.33) and +44.0% vs its 200-day average ($7.87).
- 52-week range $1.39–$15.88; today's close sits at 69% of that range, 28.6% below the 52-week high.
Oct 5, 2026 — SLS dips 0.9% to $11.63
- Closed at $11.63, -0.94% vs the prior close of $11.74. Day range $11.35–$11.77, opened at $11.77.
- Volume was 4.51M shares, 0.7x its 50-day average of 6.66M.
- Price is -5.6% vs its 50-day average ($12.32) and +48.6% vs its 200-day average ($7.83).
- 52-week range $1.39–$15.88; today's close sits at 71% of that range, 26.8% below the 52-week high.
Oct 2, 2026 — SLS jumps 3.6% to $11.74
- Closed at $11.74, +3.62% vs the prior close of $11.33. Day range $11.38–$12.00, opened at $11.50.
- Volume was 3.84M shares, 0.6x its 50-day average of 6.70M — lighter than usual.
- Price is -4.6% vs its 50-day average ($12.31) and +50.9% vs its 200-day average ($7.78).
- 52-week range $1.39–$15.88; today's close sits at 71% of that range, 26.1% below the 52-week high.
SLS latest news & SEC filings
Every SEC filing by or about SLS in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$9.61M (prior year -$6.60M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.05 (prior year -$0.07) (loss narrowed vs Jun 30, 2025)
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 27, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 25, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade SLS
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: Jul 27, 2026, May 12, 2026, Mar 19, 2026. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.61% (largest 12.0%). That is a volatile stock.
- Liquidity: about 5.30M shares (≈$52.85M) trade per day on average.
- 52-week position: $9.98 vs a range of $1.39–$15.88 (59% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 0 sales; latest: Katherine Bach Kalin bought 63,400 shares on Nov 19, 2025.
- Latest filings: 8-K Aug 11, 2026; 10-Q Aug 11, 2026; 8-K Jul 27, 2026.
- Share count: 201.95M shares outstanding (Aug 10, 2026), +91.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
SLS market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11.17 | 11.24 | 9.75 | 9.98 | 15.77M |
| Oct 15, 2026 | 11.50 | 11.92 | 11.15 | 11.34 | 4.65M |
| Oct 14, 2026 | 12.21 | 12.44 | 11.71 | 11.88 | 4.74M |
| Oct 13, 2026 | 11.74 | 12.70 | 11.69 | 12.41 | 6.40M |
| Oct 12, 2026 | 11.58 | 12.14 | 11.48 | 11.93 | 4.03M |
| Oct 9, 2026 | 11.38 | 11.81 | 11.26 | 11.65 | 4.18M |
| Oct 8, 2026 | 11.17 | 11.34 | 10.71 | 11.26 | 4.21M |
| Oct 7, 2026 | 11.28 | 11.54 | 11.15 | 11.31 | 3.13M |
| Oct 6, 2026 | 11.63 | 11.67 | 11.11 | 11.34 | 3.98M |
| Oct 5, 2026 | 11.77 | 11.77 | 11.35 | 11.63 | 4.51M |
| Oct 2, 2026 | 11.50 | 12.00 | 11.38 | 11.74 | 3.84M |
| Oct 1, 2026 | 12.15 | 12.25 | 11.20 | 11.33 | 6.22M |
| Sep 30, 2026 | 11.51 | 12.53 | 11.20 | 12.31 | 8.62M |
| Sep 29, 2026 | 11.50 | 11.64 | 11.37 | 11.51 | 3.27M |
| Sep 28, 2026 | 11.51 | 11.85 | 11.31 | 11.59 | 3.75M |
| Sep 25, 2026 | 11.99 | 12.15 | 11.50 | 11.61 | 4.45M |
| Sep 24, 2026 | 11.43 | 12.04 | 11.10 | 11.98 | 4.65M |
| Sep 23, 2026 | 11.92 | 12.14 | 11.42 | 11.52 | 3.89M |
| Sep 22, 2026 | 11.41 | 12.07 | 11.17 | 12.02 | 5.97M |
| Sep 21, 2026 | 11.59 | 11.94 | 11.13 | 11.37 | 5.64M |
About SELLAS Life Sciences
SELLAS Life Sciences (SLS) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1390478.
SLS board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Katherine Bach Kalin | Director | Jan 9, 2026 |
| David A Scheinberg | Director | Jan 9, 2026 |
| Angelos M. Stergiou | President and CEO | Jun 18, 2026 |
| Nostrand Robert L Van | Director | Jan 9, 2026 |
| John Varian | Director | Jan 9, 2026 |
| Jane Wasman | Director | Jan 9, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| John Thomas Burns | CFO | Jan 9, 2026 |
| Dragan Cicic | SVP, Chief Development Officer | Jan 9, 2026 |
| Angelos M. Stergiou | President and CEO | Jun 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Nov 19, 2025 | Katherine Bach Kalin | Buy | 63,400 | $1.59 |
| Nov 19, 2025 | Katherine Bach Kalin | Buy | 63,400 | $1.59 |
| Nov 19, 2025 | Katherine Bach Kalin | Buy | 63,400 | $1.59 |
| Nov 19, 2025 | Katherine Bach Kalin | Buy | 63,400 | $1.59 |
SLS financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-26.86M | -0.25 | $-28.39M |
| Dec 31, 2024 | — | $-30.88M | -0.50 | $-35.40M |
| Dec 31, 2023 | $0 | $-37.34M | -1.34 | $-31.41M |
| Dec 31, 2022 | $1.00M | $-41.30M | -2.13 | $-23.81M |
| Dec 31, 2021 | $7.60M | $-20.70M | -1.34 | $-26.02M |
Latest balance sheet: total assets $145.38M, total liabilities $7.73M, cash $138.34M (as of Jun 30, 2026).
SLS earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $11.05 |
| Jul 27, 2026 | 8-K Item 2.02 (results) | $10.84 |
| May 12, 2026 | 8-K Item 2.02 (results) | $5.22 |
| Mar 19, 2026 | 8-K Item 2.02 (results) | $5.20 |
| Jan 8, 2026 | 8-K Item 2.02 (results) | $3.86 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.49 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.61 |
| May 13, 2025 | 8-K Item 2.02 (results) | $1.41 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $1.21 |
| Nov 13, 2024 | 8-K Item 2.02 (results) | $1.27 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on SLS
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.